Cardiac Medical Therapy Following Coronary Artery Bypass Graft Surgery
Okrainec et al. (1) meticulously reviewed available data from randomized studies of medical treatment for postcoronary artery bypass graft (CABG) patients. Their recommendations should influence medical practice until further information comes forth in the future.
Patients undergoing CABG at varying intervals after an acute myocardial infarction (MI) are an important subgroup. They are also an important subgroup undergoing percutaneous coronary interventions. The efficacy of beta-blockers (2) and angiotensinconverting enzyme (ACE) inhibitors (3) for secondary prevention after an MI is established. No randomized controlled study has addressed the issue of their usefulness in post-MI patients who have undergone CABG. In the absence of evidence to the contrary, it is prudent to assume that these agents will not lose their efficacy after a post-MI patient undergoes CABG. Therefore, it needs to be stated explicitly that, whereas there is little evidence to suggest that beta-blockers and ACE inhibitors should be used routinely after CABG, they should be used after CABG if the patient had a prior MI. When future studies are planned, distinguishing this subgroup will be important. 
